Drug Trial Radar · NCT04382755
Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
Last checked: Nov 20, 2026Latest source record: Sep 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
May 22, 2020
Primary completion
Dec 29, 2020
Study completion Apr 9, 2021
Sponsor
- Lead sponsor
- University Hospital, GhentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- UCB Pharma
- First posted
- May 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a randomized controlled, open-label trial comparing subcutaneous Zilucoplan® with standard of care to standard of care alone. In the active group, Zilucoplan® will be administered subcutaneously once daily for 14 days or till discharge from the hospital, whichever comes first. The hypothesis of the proposed intervention is that Zilucoplan® (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote lung repair mechanisms, that lead to a 25% improvement in lung oxygenation parameters. This hypothesis is based on experiments performed in mice showing that C5a blockade can prevent mortality and prevent ARDS in mice with post-viral acute lung injury. Eligible patients include patients with confirmed COVID-19 infection suffering from hypoxic respiratory failure defined as O2 saturation below 93% on minimal 2l/min O2 therapy and/or ratio PaO2/FiO2 below 350.
Conditions
- COVID-19
Interventions
Zilucoplan®Drug
14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®
PlaceboDrug
standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in OxygenationTime frame: at predose, day 6 and day 15 (or at discharge, whichever comes first)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
OLVZ Aalst
Aalst, Belgium
AZ Sint Jan Brugge
Bruges, Belgium
Erasmus University Hospital
Brussels, Belgium
AZ Sint-Lucas
Ghent, Belgium
University Hospital Ghent
Ghent, Belgium
Jan Yperman Ziekenhuis Ieper
Ieper, Belgium
University Hospital Liège
Liège, Belgium
AZ Delta
Roeselare, Belgium
AZ Vesalius
Tongeren, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.